CDK12 and ovarian cancer: A notable deficiency in the field has been the lack of models with a stable CDK12−/− genotype, as CDK12 loss is poorly tolerated and attempts to generate long-term stable cell lines models have failed with the exception of an engineered CDK12−/− ovarian cancer line, which notably does not exhibit cisplatin or PARPi sensitivity (38–40).